Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CCR9 Antikörper (2nd Extracellular Loop)

Der Kaninchen Polyklonal anti-CCR9 Antikörper wird verwendet zum Nachweis von CCR9 in Proben von Human. Er wurde validiert für WB, FACS und LCI.
Produktnummer ABIN7886250
1.184,62 €
Zzgl. Versandkosten 20,00 € und MwSt
Lieferung nach: Deutschland
Lieferung in 8 bis 9 Werktagen

Kurzübersicht für CCR9 Antikörper (2nd Extracellular Loop) (ABIN7886250)

Target

Alle CCR9 Antikörper anzeigen
CCR9 (Chemokine (C-C Motif) Receptor 9 (CCR9))

Reaktivität

  • 78
  • 54
  • 17
  • 3
  • 3
Human

Wirt

  • 75
  • 22
  • 8
  • 4
  • 1
Kaninchen

Klonalität

  • 64
  • 44
  • 1
Polyklonal

Konjugat

  • 40
  • 9
  • 7
  • 6
  • 5
  • 5
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser CCR9 Antikörper ist unkonjugiert

Applikation

  • 61
  • 47
  • 23
  • 16
  • 14
  • 13
  • 13
  • 8
  • 5
  • 4
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
Western Blotting (WB), Flow Cytometry (FACS), Live Cell Imaging (LCI)
  • Bindungsspezifität

    • 18
    • 15
    • 8
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    2nd Extracellular Loop, AA 205-218

    Verwendungszweck

    A Rabbit Polyclonal Antibody to CCR9 Chemokine Receptor

    Kreuzreaktivität

    Human, Maus, Ratte

    Homologie

    Mouse,rat - 10,14 amino acid residues identical

    Produktmerkmale

    Anti-CCR9 (extracellular) Antibody (ABIN7043036, ABIN7044177 and ABIN7044178) is a highly specific antibody directed against an epitope of the human protein. The antibody can be used in western blot and indirect live cell flow cytometry applications. It has been designed to recognize CCR9 from rat, mouse, and human samples.

    Aufreinigung

    Affinity purified on immobilized antigen.

    Immunogen

    (C)DESTKLKSAVLTLK, corresponding to amino acid residues 205-218 of human CCR9

    Isotyp

    IgG
  • Applikationshinweise

    WB: 1:200

    FC: 5 μg per reaction

    ICC: The optimal concentration should be determined by the user

    IHC: The optimal concentration should be determined by the user

    IP: The optimal concentration should be determined by the user

    Kommentare

    Negative Control: (ABIN7235059)

    Blocking Peptide: (ABIN7235059)

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

    Konzentration

    0.8 mg/mL

    Buffer

    PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C
  • Target

    CCR9 (Chemokine (C-C Motif) Receptor 9 (CCR9))

    Andere Bezeichnung

    CCR9

    Hintergrund

    Synonyms: C-C chemokine receptor type 9, CC-CKR-9, G-protein coupled receptor 28, GPR28, GPR-9-6, CDw199

    Description: CCR9 (C-C chemokine receptor type 9) belongs to the β-chemokine receptor family of the G-protein coupled receptor superfamily. Chemokine receptors play a crucial role in cell migration and are considered to be important therapeutic targets for inflammatory diseases and in tumor chemoresistance and metastasis. In addition, high expression of CCR9 has been reported in a wide range of cancers including melanoma, ovarian cancer, lung cancer, breast cancer and colon cancer. Thus, CCR9 is considered to be a potential tumor biomarker in diagnosis and therapy of cancer1,2. Under physiological conditions, CCR9 is mainly expressed in immature T lymphocytes and on the surface of intestinal cells2.CCR9 receptor interacts with its specific ligand- chemokine ligand 25 (CCL25, thymus-expressed chemokine) in a two-step binding mechanism in which the C-terminal region of CCL25 first binds the N-terminus region and extracellular loops of the receptor followed by the binding of the N-terminus of the chemokine. The two-step biding mechanism stabilizes the receptor in an active conformation that facilitates intracellular signaling1.

    Gen-ID

    10803

    NCBI Accession

    NM_001256369

    UniProt

    P51686
Sie sind hier:
Chat with us!